The pharmaceutical companies Biogen and Eisai last week announced that a monoclonal antibody treatment reduced cognitive decline by 27% in people with early stage Alzheimer’s compared with those on a placebo after 18 months. www.science.org/content/article/news-glance-ai-regulation-renewable-energy-and-alzheimer-s-therapy? Lecanemab belongs to a class...

Article by Lalita Panicker, Consulting Editor, Views and Editor, Insight, Hindustan Times, New Delhi A technique for precisely rewriting the genetic code directly in the body has slashed “bad” cholesterol levels—possibly for life—in three people prone to dangerously high levels...